CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB032

Oral Cancer Screening and Testing

Defines lab management reimbursement criteria for oral cancer screening and testing (including HPV tumor status testing) for Blue Cross Blue Shield of Texas products; providers should review specific plan documents for applicability.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLAB032

Change TypeMaterial updates to reimbursement scope, non‑reimbursable tests, and code list

Effective DateMay 15, 2025

Next Review Date

Key ActionSubmit accurate claims with supporting documentation using valid HIPAA code sets; expect claim review and possible requests for additional documentation.

SourceLink

POLICY UPDATE CHANGES

Revised #1 for intent of test; added 'To establish HPV tumor status' language and clarified acceptable methods (mRNA E6/E7 or immunohistochemistry).

Added explicit non-reimbursable tests: salivary biomarker testing and panels that combine genetic risk factors with non-genetic biomarkers (e.g., mRNA CancerDetect).

Added procedure codes 87626 and 0429U; removed code 87623.

Document updated with literature review and revised references.

2potentially reimbursable HPV testing

2explicitly not reimbursable tests

9procedure codes listed

02/05→05/15

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLAB032

Change TypeMaterial updates to reimbursement scope, non‑reimbursable tests, and code list

Effective DateMay 15, 2025

Next Review Date

Key ActionSubmit accurate claims with supporting documentation using valid HIPAA code sets; expect claim review and possible requests for additional documentation.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Coverage criteria

Reimbursement guidance for testing related to oral cancer and HPV tumor status:

ALL of the following

ONE of
- To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma, testing for high-risk HPV by either mRNA expression testing for HPV E6/E7
- To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma, testing for high-risk HPV by immunohistochemistry
None of the following reimbursable for screening, detection, or diagnosis of oral cancer
- Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites) is not reimbursable
- Panels that incorporate genetic risk factors with non-genetic biomarkers (e.g., mRNA CancerDetect) are not reimbursable

Reimbursement is limited to the intents and methods specified above; testing outside these intents or methods should be considered non-reimbursable unless otherwise specified by plan documents.

Procedure Codes and Coding Notes

Listed procedure codesmixed

81599
82397
87624
87625
87626
88341
88342
0296U
0429U

Code inclusion note

Policy noticeThe following is not an all‑encompassing code list; inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Code list is illustrativeCodes shown in the policy are examples for billing guidance and may not reflect coverage for all products or situations.

Provider responsibilityProviders must verify coverage and eligibility with the member's specific plan before billing.

Updates may occurProcedure codes can be added or removed; refer to the policy for the most current code list when submitting claims.

Claims Submission and Documentation Requirements

Documentation Required

Submit accurate documentation and use valid HIPAA code sets

Providers are responsible for submitting accurate documentation of services performed and must submit claims using valid HIPAA-approved code sets and industry-standard coding guidelines (eg, CPT, HCPCS, ICD-10-CM/PCS, NDC, DRG, CMS NCCI). Claims are subject to review and the plan may request additional documentation.

Submit claims using valid code combinations from HIPAA-approved code sets.
Code claims according to industry-standard coding guidelines (Uniform Billing, AMA CPT, HCPCS, ICD-10-CM/PCS, NDC, DRG, CMS NCCI and related manuals).
Be prepared to provide additional documentation upon request for claim review (coverage terms, provider contracts, policies, coding logic).

Definitions and Test Methods

HPV tumor status testing — definition

DefinitionTo establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma by testing for high‑risk HPV via mRNA expression for E6/E7 or by immunohistochemistry.

Intended useSpecifically intended to determine tumor HPV status in oropharyngeal squamous cell carcinoma (not for general screening or detection).

Acceptable methodsHigh‑risk HPV mRNA expression testing targeting E6/E7 or immunohistochemistry (IHC).

Reimbursement stanceThese testing methods may be reimbursable when used to establish tumor HPV status for oropharyngeal squamous cell carcinoma, per policy criteria.